Norvasc (Amlodipine)
The raised arterial pressure is marked at more than 50 million Americans and is a major factor of the risk of development of cardiovascular diseases — one of the main reasons of death in the USA. Despite of a significant variety of available preparations, it is not possible to achieve adequate decrease of arterial pressure at the majority of patients. If not to conduct treatment there can be such complications as an insult, an atherosclerosis, heart attack, stagnant cardiac and renal insufficiency, blindness.
Norvask is the most advanced representative of the family of dihydropyridines, used in cardiology since 70th years. These medicines are applied at treatment of a high pressure and ischemic illness heart disease. They block calcium pumps in cells, expanding vessels and by that reducing resistance to a blood-groove. The operating basis of Novrask, amlodypine, is remarkable by the fact that it affects the vessels 80 times more effectively, than on a fabric of heart, and owing to it almost does not cause loss of activity of a cardiac muscle.
Indications to application
Amlodypine is designated for treatment of an arterial hypertension as means of the first order and it can be used as monotherapy for the control of a level of arterial pressure at the majority of patients. At the patients not enough reacting on any of the hypotensive preparations, the effect can be received at addition of amlodypine which was appointed in a combination with thiazide diuretic, beta-adrenergic blocking agents or inhibitors of angiotensin converting enzyme.
Amlodypine was developed as means of the first order for treatment of a myocardial ischemia caused both by organic impassability (a stable stenocardia), and by a spasm/vasoconstriction of coronary arteries (Prinzmetal’s angina or an alternative stenocardia). Amlodypine may be also applied in the cases when the clinical picture allows to assume an opportunity of existence of angiospasm/vasoconstriction though the presence of such spasm is not precisely established. Amlopydine is possible to be prescribed as means of monotherapy or in a combination with other antianginal drugs at patients, refractory to treatment by nitrates and/or beta-adrenergic blocking agents in adequate dozes.
